ContributorsPublishersAdvertisers

#Recist

StreetInsider.com

Bellicum Pharma (BLCM) Reports Positive Interim Data from Phase 1/2 GoCAR-T Studies, Announces 20.6M Share Private Placement at $1.70/sh

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced positive interim data from its ongoing Phase 1/2 GoCAR-T clinical trials, including a confirmed partial response (PR) in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. Bellicum has also entered into an agreement for a $35 million private placement of equity securities with two biotechnology specialist investment funds. Proceeds from the financing will be used to support ongoing clinical development of BPX-601 and BPX-603.
MEDICAL & BIOTECH
targetedonc.com

FDA Orphan Drug Designation Granted to INBRX-109 for Chondrosarcoma

With an orphan drug designation from the FDA, INBRX-109 may be on track to become the first FDA-approved treatment for chondrosarcoma. The FDA has granted an orphan drug designation to INBRX-109 for the treatment of chondrosarcoma, according to a press release by Inhibrx, Inc.1. INBRX-109 is a tetravalent death receptor...
INDUSTRY
Picture for FDA Orphan Drug Designation Granted to INBRX-109 for Chondrosarcoma
targetedonc.com

FDA 'Fast Tracks' Arfolitixorin for Metastatic Colorectal Cancer

After 40 years, a novel agent may be on the fast track to becoming the first drug to improve the standard of care for patients with metastatic colorectal cancer. The FDA has granted fast track designation to arfolitixorin, stabilized and biologically active pure form of folate, for treatment of patients with metastatic colorectal cancer (mCRC), announced Isofol Medical AB, in a press release.1.
CANCER
Picture for FDA 'Fast Tracks' Arfolitixorin for Metastatic Colorectal Cancer
TRENDING TOPICS
oncnursingnews.com

Tidutamab Induces Best Overall Response of Stable Disease in Advanced Neuroendocrine Tumors

Patients with neuroendocrine tumors across various origins experienced favorable responses after receiving tidutamab. Preliminary data showed that patients with advanced, well-differentiated neuroendocrine tumors (NETs) of pancreatic, gastrointestinal (GI), lung, and undetermined origin, experienced best overall response of stable disease after receiving tidutamab (previously XmAb18087). Findings from the trial (NCT03411915) were recently presented at the 2021 NANETS Annual Symposium.1.
CANCER
Nature.com

Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study

In patients with metastatic colorectal cancer (mCRC), baseline circulating tumour DNA (ctDNA) variant allele fraction (VAF) might serve as a surrogate of disease burden and should be evaluated in comparison with CEA and RECIST-defined sum of target lesions. Methods. In this pre-planned analysis of the VALENTINO trial, we included patients...
CANCER
oncnursingnews.com

Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial Cancer

A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. A long-term follow-up analysis of a phase 1b/2 study found that patients with previously treated, advanced endometrial cancer experienced durable responses...
CANCER
targetedonc.com

MT-6402 Lands FDA Fast Track Designation for PD-L1+ Non–Small Cell Lung Cancer

The FDA has granted fast track designation to MT-6402 for the treatment of patients with advanced non–small cell lung cancer expressing PD-1. The FDA has granted fast track designation to MT-6402 for the treatment of patients with advanced non–small cell lung cancer (NSCLC) expressing PD-1, according to a press release issued by Molecular Templates, Inc.1.
CANCER
contemporaryobgyn.net

Lenvatinib plus pembrolizumab displays efficacy in advanced endometrial cancer

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096). The combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) induced durable responses with a manageable safety profile...
CANCER
cancernetwork.com

Hidalgo Medina, MD, PhD, Discusses the Use of Motixafortide/Pembrolizumab and FOLFIRI in PDAC

For Pancretic Cancer Awareness month, CancerNetwork® spoke with Manuel Hidalgo Medina, MD, PhD, about the importance of the phase 2 COMBAT/KEYNOTE-202 trial examining motixafortide and pembrolizumab plus nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic ductal adenocarcinoma. Data from the phase 2 COMBAT/KEYNOTE 202 trial (NCT02826486), which assessed the...
CANCER
onclive.com

Sacituzumab Govitecan Meets ORR End Point in Chinese Patients With Metastatic TNBC

Sacituzumab govitecan-hziy significantly improved overall response rate in Chinese patients with metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy (marketed as Trodelvy in the United States) significantly improved overall response rate (ORR) in Chinese patients with metastatic triple-negative breast cancer (mTNBC), meeting the primary end point of the phase 2b EVER-132-001 trial (NCT04454437).1.
CANCER
drpgazette.com

Checkmate Pharmaceuticals (NASDAQ:CMPI) Stock Continues to Trade in a Range

Last Friday the clinical stage biotech company Checkmate Pharmaceuticals (NASDAQ:CMPI) saw its stock trading within a range. However, at the same time, it should be noted that stocks trading within a range can also break out strongly and hence, it could be a good move to keep an eye on the Checkmate stock nonetheless.
INDUSTRY
pulse2.com

Iovance Biotherapeutics (IOVA) Stock: Why The Price Increased Today

The stock price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) increased by over 4% pre-market today. This is why it happened. The stock price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) – a late-stage biotechnology company developing novel T cell-based cancer immunotherapies – increased by over 4% pre-market today. Investors are responding positively to the company announcing clinical data for lifileucel in combination with pembrolizumab in patients with advanced cancers were presented in an oral session at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
MARKETS
targetedonc.com

COM701 With Nivolumab and BMS-986207 Show Preliminary Safety/Tolerability in Advanced Solid Tumors

Novel immuno-oncology agent, COM701 in combination with nivolumab and BMS-986207 may be safe for the treatment of patients with advanced solid tumors. In patients with advanced solid tumors, the investigational combination of COM701 with nivolumab (Opdivo) and BMS-986207 was found to be well-tolerated with a favorable safety profile, according to preliminary results (NCT04570839) presented in a poster during the 2021 Society of Immunotherapy for Cancer (SITC) Annual Meeting.
HEALTH
onclive.com

Lenvatinib Plus Pembrolizumab Displays Strong Efficacy in Advanced Endometrial Cancer

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096). The combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) induced durable responses with a manageable safety profile...
CANCER
onclive.com

Tidutamab Shows Early Tolerability, Active Immune Profile in Advanced Neuroendocrine Tumors

Tidutamab was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors of pancreatic, gastrointestinal, lung and undetermined origin. Tidutamab (previously XmAb18087) was found to be well tolerated with a best overall response of stable disease in patients with advanced,...
CANCER
targetedonc.com

Ripretinib Maintains PFS Benefit and Shows Favorable OS in Advanced GIST

Full results from the phase 3 INVICTUS trial show stable progression-free survival advantage and improved overall survival with ripretinib in patients with an advanced gastrointestinal stromal tumor. Ripretinib (Qinlock) treatment in patients with advanced gastrointestinal stromal tumor (GIST) showed a stable median progression-free survival (PFS) with no change since the...
HEALTH
targetedonc.com

Global Phase 3 Study Explores Belzutifan/Lenvatinib Doublet in Advanced RCC

The novel combination of belzutifan and lenvatinib will be tested against cabozantinib in a phase 3 clinical trial of patients with advanced renal cell carcinoma. Enrollment has begun in the phase 3 study of belzutifan (Welireg) in combination with lenvatinib (Lenvima) versus cabozantinib (Cabometyx) in patients with advanced renal cell carcinoma (RCC) after anti-PD-1/PD-L1 therapy, according to a poster presented during the 2021 International Kidney Cancer Symposium: North America.
SCIENCE
verywellhealth.com

How Do We Know If Chemotherapy Is Working?

If you're undergoing cancer treatment, your doctor may order a set of tests and scans to determine how your cancer is reacting to it. This standardized testing is called RECIST, an acronym for "response evaluation criteria in solid tumors." RECIST is a standard system to measure how cancer responds to...
CANCER
StreetInsider.com

Gilead Sciences (GILD) and Everest Medicine Announces Phase 2b Study of Sacituzumab Govitecan Meets Primary Overall Response Rate Endpoint

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Gilead Sciences, Inc. (Nasdaq: GILD) today reported that the Everest Medicines sponsored Phase 2b EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy® in the United States) met its primary endpoint of overall response rate (ORR) in metastatic triple-negative breast cancer (TNBC).
MEDICAL & BIOTECH
YOU MAY ALSO LIKE